Interview: Altan Eyes Opportunities In US Pain Market
The Irish specialty pharma has made its first filing in the US with an infusion of acetaminophen that Altan hopes will break the monopoly of Mallinckrodt's Ofirmev.
You may also be interested in...
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.
The University of Nottingham spin-out has raised £7.5m for a candidate that could halt the progression of peripheral arterial disease in diabetics.